Kjelsåsveien 168 B
217 articles with Nordic Nanovector
Reference is made to the stock exchange announcement on 18 October 2019 regarding the successful completion of Nordic Nanovector ASA's private placement of new shares The Private Placement is divided into two tranches, as further explained in the stock exchange announcement on 18 October 2019.
The Company announces that it has raised NOK 242,525,624 in gross proceeds through a private placement of 11,023,892 new shares The Private Placement was completed at a subscription price of NOK 22.00 per share, which was determined through an accelerated book-building process.
Reference is made to the announcement by Nordic Nanovector ASA on 18 October 2019 concerning a private placement with gross proceeds in the amount of NOK 242 525 624 and that the Company is considering to conduct a repair offering of up to 2,204,778 new shares with non-tradeable subscription rights to eligible shareholders.
Nordic Nanovector Presentations at the Annual Congress of the European Association of Nuclear Medicine (EANM) - Oct. 9, 2019
Nordic Nanovector ASA announces that the Company and its collaborators at Orano Med will present data and analyses from preclinical studies with 212Pb-NNV003, a CD37 targeting alpha-radioimmunotherapy for the treatment of leukaemia and lymphoma at the 2019 Annual Congress of the European Association of Nuclear Medicine.
Nordic Nanovector Signs Global Clinical and Commercial Agreement With ITM for the Supply of No-carrier-added Lutetium-177
Nordic Nanovector ASA announces that it has signed a long-term global supply agreement with a subsidiary of ITM Isotopen Technologien München AG, Isotope Technologies Garching GmbH to ensure the supply of high quality, no-carrier-added Lutetium-177, a key component of Betalutin® for R&D, clinical and commercial uses.
ITM Isotopen Technologien München AG announced that ITM´s subsidiary, ITG Isotope Technologies Garching GmbH and Nordic Nanovector ASA have signed long-term global supply agreements for the medical radioisotope no-carrier-added Lutetium-177 EndolucinBeta® to support R&D, clinical and commercial supply of Betalutin®.
Nordic Nanovector ASA announces the appointment of Dr Gabriele Elbl as Vice President Global Regulatory Affairs.
Nordic Nanovector ASA: Increased Share Capital Following Exercise of Employee Share Options - Sept. 19, 2019
One former employee and a participant in the Company's previous share option program, not being a primary insider, has exercised a total number of 5,775 options through exercise of a corresponding number of free-standing warrants.
Nordic Nanovector ASA (OSE: NANO) will host an R&D day in Oslo.
Nordic Nanovector ASA announces that its CEO, Eduardo Bravo, will participate and present at the following upcoming investor conferences during September:
Nordic Nanovector ASA announces that it will host a R&D Day in Oslo on Tuesday, 17 September 2019 from 9:30am to 12:30pm CEST.
Rosemarie Corrigan has, 23 August, purchased 2,436 shares in Nordic Nanovector ASA at an average share price of NOK 24.56 per share.
With reference to the previous notification of trade, the correct number of shares purchased, 23 August 2019, by Malene Brondberg is not 1,722 shares, but 3,900 shares in Nordic Nanovector ASA at an average share price of NOK 25.38 per share.
Nordic Nanovector ASA announces its results for the second quarter and first half 2019.
Nordic Nanovector ASA announces the appointment of Dr Lars Nieba as Chief Technology Officer and a member of the executive management team.
Nordic Nanovector ASA: Invitation to Second Quarter and First Half 2019 Results Presentation and Webcast
Nordic Nanovector ASA announces that it will report its results for the second quarter and first half 2019 on Thursday, 22 August 2019.
Nordic Nanovector Completes Patient Enrolment Into Phase 1 Trial of Betalutin® in Diffuse Large B-cell Lymphoma (DLBCL)
Nordic Nanovector ASA (OSE: NANO) announces that the final patient has been enrolled in the LYMRIT 37-05 clinical trial of Betalutin® (177Lu-satetraxetan-lilotomab) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not eligible for stem cell transplantation.
Reference is made to the stock exchange notice published by Nordic Nanovector ASA on 31 May 2019 where the Company announced that the board of directors of the Company had resolved to increase the Company's share capital in connection with the exercise of RSUs.
Nordic Nanovector Presentations at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2019 Annual Meeting
Nordic Nanovector ASA announces that the company and its collaborators will present data and analyses from its preclinical studies with Betalutin® and with 212Pb-NNV003, a next-generation targeted alpha therapy comprising Nordic Nanovector's chimeric anti-CD37 antibody coupled with the alpha-particle-generator lead-212, at the Society of Nuclear Medicine & Molecular Imaging 2019 Annual Meeting, to be held in Anaheim, CA, USA on 22-24 June.
Nordic Nanovector to Present Preclinical Studies With 212Pb-NNV003, a Novel CD37-specific Targeted Alpha Therapy for CLL and NHL, at TRP 2019
Nordic Nanovector ASA announces that its Chief Scientific Officer, Jostein Dahle, will present results from preclinical studies with 212PB-NNV003 at the Targeted Radiopharmaceuticals Summit taking place in Munich, Germany on 12-13 June.